Abstract
Background: The actinobacterium Tropheryma whipplei was detected 20 years ago by molecular techniques, and following its culture has been characterized as the cause of a systemic infection known as Whipple's disease (WD). T. whipplei occurs in the environment, is prevalent only in humans, is believed to be transmitted via oral routes and to be host dependent. Key Messages: The classical form of T. whipplei infection, i.e. classical WD (CWD), is rare. It is well defined as slowly progressing chronic infection with arthralgia, diarrhea and weight loss, mostly in middle-aged men. However, current research revealed a much broader spectrum of clinical features associated with T. whipplei infection. Thus, T. whipplei may cause acute and transient infections (observed primarily in children) and the bacterium, which is found in soil and water, occurs in asymptomatic carriers as well as in CWD patients in clinical remission. In addition, T. whipplei affects isolated and localized body compartments such as heart valves or the central nervous system. Subtle immune defects and HLA associations have been described. New findings indicate that the progression of asymptomatic T. whipplei infection to clinical WD may be associated with medical immunosuppression and with immunomodulatory conditions. This explains that there is a discrepancy between the widespread occurrence of T. whipplei and the rareness of WD, and that T. whipplei infection triggered by immunosuppression presents with protean clinical manifestations. Conclusions: This review highlights recent findings and the clinical spectrum of infection with T. whipplei and WD, focusing specifically on the role of host immunity and immunosuppression. Current concepts of the pathogenesis, diagnosis and therapy are discussed.
References
1.
Dobbins WO III: Whipple's Disease. Springfield, Charles C Thomas, 1987.
2.
Relman DA, Schmidt TM, Macdermott RP, et al: Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992;327:293-301.
3.
Schoedon G, Goldenberger D, Forrer R, et al: Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whipplei. J Infect Dis 1997;176:672-677.
4.
Raoult D, Birg ML, La Scola B, et al: Cultivation of the bacillus of Whipple's disease. N Engl J Med 2000;342:620-625.
5.
La Scola B, Fenollar F, Perreal C, Raoult D: Epidemiologic implications of the first isolation and cultivation of Tropheryma whipplei from a saliva sample. Ann Intern Med 2011;154:443-444.
6.
Li W, Fenollar F, Rolain JM, et al: Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 2008;154:521-527.
7.
Bentley S, Maiwald M, Murphy LD, et al: Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet 2003;361:637-644.
8.
Schöniger-Hekele M, Petermann D, Weber B, et al: Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 2007;73:2033-2035.
9.
Fenollar F, Trani M, Davoust B, et al: Prevalence of asymptomatic Tropheryma whipplei carriage among humans and nonhuman primates. J Infect Dis 2008;197:880-887.
10.
Keita AK, Mediannikov O, Ratmanov P, Diatta G, Bassene H, Roucher C, Tall A, Sokhna C, Trape JF, Raoult D, Fenollar F: Looking for Tropheryma whipplei source and reservoir in rural Senegal. Am J Trop Med Hyg 2013;88:339-343.
11.
Fenollar F, Keita AK, Buffet S, Raoult D: Intrafamilial circulation of Tropheryma whipplei, France. Emerg Infect Dis 2012;18:949-955.
12.
Marth T: Untersuchungen zur Klinik, Therapie und zellulären Immunität des M. Whipple; University of Bonn, 1993.
13.
Dutly F, Altwegg M: Whipple's disease and ‘Tropheryma whippelii'. Clin Microbiol Rev 2001;4:561-583.
14.
Martinetti M, Biagi F, Badulli C, et al: The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple's disease. Gastroenterology 2009;136:2289-2294.
15.
Marth T, Neurath M, Cuccherini BA, et al: Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology 1997;113:442-448.
16.
Geelhaar A, Moos V, Schinnerling K, et al: Specific and nonspecific B-cell function in the small intestines of patients with Whipple's disease. Infect Immun 2010;78:4589-4592.
17.
Moos V, Kunkel D, Marth T, et al: Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease. J Immunol 2006;177:2015-2022.
18.
Marth T, Kleen N, Stallmach A, et al: Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology 2002;123:1468-1477.
19.
Schinnerling K, Moos V, Geelhaar A, et al: Regulatory T cells in patients with Whipple's disease. J Immunol 2011;187:4061-4067.
20.
Marth T, Roux M, von Herbay A, Meuer SC, Feurle GE: Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol 1994;72:217-226.
21.
Moos V, Schmidt C, Geelhaar A, et al: Impaired immune functions of monocytes and macrophages in Whipple's disease. Gastroenterology 2010;138:210-220.
22.
Desnues B, Lepidi H, Raoult D, et al: Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages. J Infect Dis 2005;192:1642-1646.
23.
Gorvel L, Al Moussawi K, Ghigo E, et al: Tropheryma whipplei, the Whipple's disease bacillus, induces macrophage apoptosis through the extrinsic pathway. Cell Death Dis 2010;1:e34.
24.
Dobbins WO 3rd: Is there an immune deficit in Whipple's disease? Dig Dis Sci 1981;26:247-252.
25.
Kalt A, Schneider T, Ring S, Hoffmann J, Zeitz M, Stallmach A, Persing DH, Marth T: Decreased levels of interleukin-12p40 in the serum of patients with Whipple's disease. Int J Colorectal Dis 2006;21:114-120.
26.
Inoue R, Kondo N, Kobayashi Y, Fukutomi O, Orii T: IgG2 deficiency associated with defects in production of interferon-gamma; comparison with common variable immunodeficiency. Scand J Immunol 1995;41:130-134.
27.
Sanders LA, van de Winkel JG, Rijkers GT, Voorhorst-Ogink MM, de Haas M, Capel PJ, Zegers BJ: Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994;170:854-861.
28.
Raoult D, Fenollar F, Rolain JM, Minodier P, Bosdure E, Li W, Garnier JM, Richet H: Tropheryma whipplei in children with gastroenteritis. Emerg Infect Dis 2010;16:776-782.
29.
Keita AK, Bassene H, Tall A, Sokhna C, Ratmanov P, Trape JF, Raoult D, Fenollar F: Tropheryma whipplei: a common bacterium in rural Senegal. PLoS Negl Trop Dis 2011;5:e1403.
30.
Geissdorfer W, Moos V, Moter A, Loddenkemper C, Jansen A, Tandler R, Mirguet AJ, Raoult D, Bogdan C, Schneider T: High frequency of Tropheryma whipplei in culture-negative endocarditis. J Clin Microbiol 2012;50:216-222.
31.
Love SM, Morrison L, Appleby C, Modi P: Tropheryma whipplei endocarditis without gastrointestinal involvement. Interact Cardiovasc Thorac Surg 2012;15:161-163.
32.
Fenollar F, Puéchal X, Raoult D: Whipple's disease. N Engl J Med 2007;356:55-66.
33.
Marth T, Raoult D: Whipple's disease. Lancet 2003;361:239-246.
34.
Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T: Immunosuppressive therapy in Whipple's disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 2005;100:1167-1173.
35.
Lagier JC, Lepidi H, Raoult D, Fenollar F: Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore) 2010;89:337-334.
36.
Compain C, Sacre K, Puéchal X, Klein I, Vital-Durand D, Houeto JL, De Broucker T, Raoult D, Papo T: Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine (Baltimore) 2013;92:324-330.
37.
Marth T: Complicated Whipple's disease and endocarditis following tumor necrosis factor inhibitors. World J Cardiol 2014;6:1278-1284.
38.
Razonable RR, Pulido JS, Deziel PJ, Dev S, Salomão DR, Walker RC: Chorioretinitis and vitreitis due to Tropheryma whipplei after transplantation: case report and review. Transpl Infect Dis 2008;10:413-418.
39.
Gillen CD, Coddington R, Monteith PG, Taylor RH: Extraintestinal lymphoma in association with Whipple's disease. Gut 1993;11:1627-1629.
40.
Gruner U, Goesch P, Donner A, Peters U: Whipple disease and non-Hodgkin lymphoma. Z Gastroenterol 2001;41:305-309.
41.
Feurle GE, Junga NS, Marth T: Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. Gastroenterology 2010;138:478-86.
42.
Wang S, Ernst LM, Smith BR, Tallini G, Howe JG, Crouch J, Cooper DL: Systemic Tropheryma whipplei infection associated with monoclonal B-cell proliferation: a Helicobacter pylori-type pathogenesis? Arch Pathol Lab Med 2003;12:1619-1622.
43.
Fest T, Pron B, Lefranc MP, Pierre C, Angonin R, de Wazières B, Soua Z, Dupond JL: Detection of a clonal BCL2 gene rearrangement in tissues from a patient with Whipple disease. Ann Intern Med 1996;8:738-740.
44.
Rouillon A, Menkes CJ, Gerster JC, Perez-Sawka I, Forest M: Sarcoid-like forms of Whipple's disease. Report of 2 cases. J Rheumatol 1993;20:1070-1072.
45.
Dzirlo L, Hubner M, Mueller C, Blaha B, Formann E, Dellinger C, Petzelbauer P, Muellauer L, Huber K, Kneussl M, Gschwantler M: A mimic of sarcoidosis. Lancet 2007;369:1832.
46.
Niemczyk S, Filipowicz E, Wozniacki L, Grochowski J, Zaleski L, Grzejszczak A, Ptasinska AP, Koperski L, Rowinska JM: Renal amyloidosis in Whipple disease: a case report. Cases J 2009;2:8444.
47.
Dray X, Vahedi K, Delcey V, Lavergne-Slove A, Raskine L, Bergmann JF, Marteau P: Mycobacterium avium duodenal infection mimicking Whipple's disease in a patient with AIDS. Endoscopy 2007;39(suppl 1):E296-E297.
48.
Lozupone C, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, Sodergren E, Mitreva M, Abubucker S, Martin J, Yao G, Campbell TB, Flores SC, Ackerman G, Stombaugh J, Ursell L, Beck JM, Curtis JL, Young VB, Lynch SV, Huang L, Weinstock GM, Knox KS, Twigg H, Morris A, Ghedin E, Bushman FD, Collman RG, Knight R, Fontenot AP; Lung HIV Microbiome Project: Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med 2013;187:1110-1117.
49.
Meier-Willersen HJ, Maiwald M, von Herbay A: Whipple's disease associated with opportunistic infections. Dtsch Med Wochenschr 1993;118:854-860.
50.
Fenollar F, Lepidi H, Gerolami R, Drancourt H, Raoult D: Whipple disease associated with giardiasis. J Infect Dis 2003;188:828-834.
51.
Arnold CA, Moreira RK, Lam-Himlin D, De Petris G, Montgomery E: Whipple disease a century after the initial description: increased recognition of unusual presentations, autoimmune comorbidities, and therapy effects. Am J Surg Pathol 2012;36:1066-1073.
52.
Feurle GE, Moos V, Schinnerling K, et al: The immune reconstitution inflammatory syndrome in Whipple disease: a cohort study. Ann Intern Med 2010;153:710-717.
53.
Biagi F, Trotta L, Di Stefano M, et al: Previous immunosuppressive therapy is a risk factor for immune reconstitution inflammatory syndrome in Whipple's disease. Dig Liver Dis 2012;44:880-882.
54.
Davis TD, McBee JW, Borland JL, Kurtz SM, Ruffin JM: The effect of antibiotic and steroid therapy in Whipple's disease. Gastroenterology 1963;44:112-116.
55.
Comer GM, Brandt LJ, Abissi CJ: Whipple's disease: a review. Am J Gastroenterol 1983;78:107-114.
56.
Holt PR, Isselbacher KJ, Jones CM: The reversibility of Whipple's disease. Report of a case, with comments on the influence of corticosteroid therapy. N Engl J Med 1961;264:1335-1339.
57.
Fenollar F, Lauira S, Lepidi H, Rolain JM, Raoult D: Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis 2008;47:659-667.
58.
Lagier JC, Fenollar F, Lepidi H, Giorgi R, Million M, Raoult D: Treatment of classic Whipple's disease: from in vitro results to clinical outcome. J Antimicrob Chemother 2014;69:219-227.
59.
Feurle GE, Moos V, Blaker H, et al: Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim-sulfamethoxazole in Whipple's disease. J Inf 66;2013:263-270.
60.
Lagier JC, Fenollar F, Lepidi H, et al: Evidence of lifetime susceptibility to Tropheryma whipplei in patients with Whipple's disease. J Antimicrob Chemother 2011;66:1188-1189.
61.
Schneider T, Moos V, Loddenkemper C, et al: Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008;8:179-190.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
